



### Teva Pharmaceuticals – Recall of Amikacin Injection

- On July 29, 2016, [Teva Pharmaceuticals announced](#) a consumer-level recall of some lots of [amikacin injection](#) due to the presence of glass particulate matter.
  - The use of or exposure to the recalled product may cause adverse health consequences, and the probability of serious adverse health consequences is likely low.
- The recalled lots (listed below) were shipped beginning July 10, 2015.

Product Description	NDC #	Lot #	Expiration Date
Amikacin sulfate injection, 500 mg/2 mL (250 mg/mL)	00703-9032-03	7080315, 7400315, 7410315	3/2017
		7980415	4/2017
Amikacin sulfate injection, 1 g/ 4 mL (250 mg/mL)	00703-9040-03	2381114, 2771114	11/2016
		4760915	9/2017

- Amikacin sulfate injection is indicated in the short-term treatment of serious infections due to susceptible strains of gram-negative bacteria, including *Pseudomonas* species, *Escherichia coli*, species of indole-positive and indole-negative *Proteus*, *Providencia* species, *Klebsiella-Enterobacter-Serratia* species and *Acinetobacter (Mima-Herellea)* species.
- Anyone with recalled product should immediately discontinue distributing or dispensing any units from the recalled lots and contact Inmar at **800-967-5952** for return information.
- For medical-related questions, contact Teva at **888-838-2872**.

### Action Plan

- Clinical Services will conduct mailings to member(s) that may be affected by the amikacin injection recall, and to providers who prescribed for the drug recently.
- Information regarding the amikacin injection recall will be posted on the [optumrx.com](#) portals.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.